Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm (Nasdaq: KPTI) announced that its senior management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 10:30 a.m. ET in New York.

A live webcast will be available under the company’s Investor "Events & Presentations" page and the presentation will be available for replay following the event.

Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 800 restricted stock units (RSUs) to one newly hired employee, effective October 31, 2025, under the company’s 2022 Inducement Stock Incentive Plan.

The award was made as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over three years with 33 1/3% vesting on each anniversary of the grant date, subject to continued service through each vesting date.

Karyopharm (Nasdaq: KPTI) reported Q3 2025 total revenue of $44.0 million and U.S. XPOVIO net product revenue of $32.0 million (up 8.5% year-over-year). The company reaffirmed full-year 2025 revenue guidance of $140M–$155M and U.S. XPOVIO guidance of $110M–$120M. The Phase 3 SENTRY myelofibrosis trial completed enrollment with 353 patients, with top-line data expected in March 2026. R&D and SG&A full-year ranges were lowered to $235M–$245M. Karyopharm reported a Q3 net loss of $33.1M and stated existing liquidity is expected to fund operations into the second quarter of 2026.

Karyopharm (Nasdaq: KPTI) will report third quarter 2025 financial results on Monday, November 3, 2025. Management will host a conference call and live audio webcast at 8:00 a.m. ET the same day to discuss results and company updates.

Investors may join by phone at (800) 836-8184 (U.S.) or (646) 357-8785 (international) and should dial at least 10 minutes early. A live webcast and accompanying slides will be available under Events & Presentations on the company's Investor website, with an archived webcast posted about two hours after the event.

Karyopharm (Nasdaq: KPTI) announced financing and capital-structure transactions expected to provide approximately $100 million of flexibility and additional capital, extending its cash runway into the second quarter of 2026. The transactions include new term loans, convertible-note exchanges, a private placement expected to raise about $8.75 million, and warrant repricings to an exercise price of $6.64. Preliminary Q3 2025 revenue is expected at $42–$44M with U.S. XPOVIO net product revenue of ~$32M. Cash as of Sept 30, 2025 is estimated at ~$46M before financing proceeds. Top-line Phase 3 SENTRY myelofibrosis data remain on track for March 2026.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has announced the granting of 333 restricted stock units (RSUs) to one newly-hired employee. The grant was made on September 30, 2025, under the company's 2022 Inducement Stock Incentive Plan.

The RSUs will vest over a three-year period, with one-third of the units vesting annually on the grant date anniversary. Vesting is contingent upon the employee's continued service with Karyopharm.

Karyopharm Therapeutics (Nasdaq: KPTI) has completed enrollment in its Phase 3 SENTRY trial, evaluating selinexor in combination with ruxolitinib for JAKi-naïve myelofibrosis patients. The trial enrolled 353 patients with top-line results expected in March 2026.

The study aims to assess if selinexor plus ruxolitinib could become the first approved combination therapy for myelofibrosis. The trial's co-primary endpoints include spleen volume response rate ≥35% at week 24 and the average change in absolute total symptom score over 24 weeks versus baseline. Patients were randomized 2-to-1 to receive either 60mg weekly selinexor with ruxolitinib or placebo with ruxolitinib.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 466 restricted stock units (RSUs) to two newly-hired employees as of August 31, 2025. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan.

The RSUs will vest over three years, with 33 1/3% vesting annually. Additionally, the RSUs include acceleration provisions in case of a change in control event followed by qualifying employment termination.

Karyopharm Therapeutics (Nasdaq: KPTI) reported Q2 2025 financial results with total revenue of $37.9 million, including U.S. XPOVIO net product revenue of $29.7 million, up 6% year-over-year. The company reaffirmed its full-year 2025 total revenue guidance of $140-155 million while updating U.S. XPOVIO revenue guidance to $110-120 million.

Key developments include the imminent completion of patient screening for the Phase 3 SENTRY trial in myelofibrosis, with top-line results expected in March 2026. However, the company faces financial challenges with $52.0 million in cash as of June 30, 2025, down from $109.1 million at year-end 2024. Karyopharm is actively exploring financing transactions and strategic alternatives to extend its cash runway beyond the October 2025 maturity of its convertible notes.